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Abstract
Background: Several long noncoding RNAs (lncRNAs) are involved in oncogenesis.
Methods and Results: Our microarray analysis showed that numerous lncRNAs are dysregulated in
hypopharyngeal squamous cell carcinoma (HSCC) tumor tissues as compared with normal tissues. Among those
lncRNAs, urothelial carcinoma-associated 1 (UCA1) has been found to have an oncogenic role in HSCC. We
confirmed the upregulation of UCA1 in HSCC by assessing its expression levels in a cohort of 53 patient tumors
and paired non-tumor samples. In addition, we found that high UCA1 expression was significantly associated with
advanced T category, late clinical stage, greater lymphatic invasion, and worse prognosis. Furthermore, in vitro
experiments demonstrated that UCA1 functioned as an oncogene by promoting the proliferation and invasion and
preventing the apoptosis of HSCC cells.
Conclusions: Taken together, our findings for the first time identify the role of UCA1 as a tumor promoter and a pro-
metastatic factor in HSCC, demonstrating that UCA1 is a potential prognostic biomarker and therapeutic target in HSCC.
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Background
Hypopharyngeal squamous cell carcinoma (HSCC), a
malignant tumor arising from the mucosa of the upper
aerodigestive tract, accounts for 5% of all squamous cell
carcinomas in the head and neck [1, 2]. Patients with
early-stage HSCC have a 5-year overall survival rate as
high as 70% [3]; however, HSCC is seldom diagnosed at
its early stages because early-stage HSCC causes no ob-
vious symptoms. Thus, approximately 70–85% of HSCCs
are diagnosed at stage III or IV, and the 5-year overall
survival rate of patients with stage III or IV HSCC is
only 15–45% [4]. Despite recent improvements in avail-
able treatment strategies for HSCC, which include pri-
mary surgery with pre- or postoperative radiotherapy and
primary radiotherapy with chemotherapy, the prognosis of
HSCC patients with late-stage disease is still far from sat-
isfactory. Therefore, it is imperative to identify sensitive
and specific progression and prognostic biomarkers that
facilitate the early diagnosis of HSCC and might serve as
potential therapeutic targets in the disease.
Long noncoding RNAs (lncRNAs)—non–protein-cod-
ing RNAs longer than 200 nucleotides—may serve as
novel biomarkers and therapeutic targets in cancer. Pre-
vious studies have shown that lncRNAs are pervasively
transcribed and that some lncRNAs can regulate gene
expression at transcriptional and posttranscriptional
levels by interacting with nucleic acids or proteins [5–7].
In addition, lncRNAs have been widely implicated in
diverse biological processes, including cell proliferation,
cell differentiation, and chromosome inactivation [8, 9].
Increasing evidence demonstrates that various cancers,
including breast cancer, lung cancer, pancreatic cancer,
osteosarcoma, hepatocellular carcinoma, and leukemia,
have aberrant lncRNA expression [10–13].
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One of lncRNAs that show promise as a potential bio-
marker of HSCC is urothelial carcinoma-associated 1
(UCA1). UCA1 is a well-characterized lncRNA that was
initially identified in urinary bladder cancer tissues, where it
was found to significantly enhance bladder cancer cells’
tumorigenicity and invasive potential in vitro and in vivo
[14]. UCA1, which also functions as a tumor promoter in
breast cancer, colorectal cancer, gastric cancer, and
esophageal squamous cell carcinoma [15–18], is closely re-
lated to the prognosis of a variety of cancers; for example,
Han et al. found that high UCA1 expression indicated
worse prognosis in colorectal cancer [16]. In a previous
microarray analysis, we found that UCA1 was one of
mostly overexpressed in HSCC tissue [19]. However, the
role of UCA1 in HSCC remains unclear.
In this study, we first validated the expression of several
mostly altered lncRNAs in HSCC patients; we found that
UCA1 is one of mostly upregulated (top 3) in HSCC
tissues compared with adjacent non-tumor tissues and
then determined that its expression is closely linked to
HSCC patients’ clinicopathological characteristics and
prognosis. Furthermore, in vitro experiments established
that UCA1 has roles in cell apoptosis, proliferation, and
invasion in HSCC, suggesting that UCA1 is an important
prognostic biomarker and treatment target for HSCC.
Methods
Patients and tissue samples
HSCC specimens and corresponding adjacent normal
tissues were obtained from 53 HSCC patients who
underwent surgery in the Department of Otolaryngology
at the Qilu Hospital of Shandong University from March
2011 to December 2011. All HSCC specimens were con-
firmed by pathological diagnosis, and all patients under-
went hypopharyngeal tumor resection plus ipsilateral
modified neck dissection. None of the 53 patients re-
ceived chemoradiotherapy or biotherapy before surgery.
All patients received radiotherapy after surgery.
The clinicopathological information were obtained from
patients’ history record including patient age, overall sur-
vival duration, tumor cell differentiation, T category, clinical
disease stage, and lymph node status. The TNM staging
system follows the standard of the International Union
Against Cancer. Patients returned for follow-up visits once
every 3 months until March 2016; 4 patients were lost to
follow up. Before undergoing surgery, all patients provided
their written informed consent for their tissues to be used
in the study. The study protocol was approved by the Ethics
Committee of the Qilu Hospital of Shandong University.
Cell cultures
The only available HSCC cell line, FaDu, was purchased
from the Shanghai Institute of Biology and maintained
in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum (FBS; Gibco, Grand Island,
NY, USA) in a humidified atmosphere containing 5%
CO2 at 37°C.
RNA extraction and quantitative real-time polymerase
chain reaction
To extract total RNA from human tissue samples, we used
Trizol reagent (Takara, Otsu, Japan) according to the
manufacturer’s instructions. We used a NanoDrop ND-
1000 spectrophotometer (Thermo Scientific, Wilmington,
DE, USA) to measure RNA concentration and purity. We
subjected 2 μg of RNA from each tissue sample to cDNA
synthesis using a reverse transcription kit (Takara). Quan-
titative real-time polymerase chain reaction (qRT-PCR)
was performed with SYBR Green Real-Time PCR Mas-
ter Mix (Toyobo, Osaka, Japan) and the LightCycler
480 II System (Roche, Basel, Switzerland). UCA1 and
β-actin were amplified in triplicate using an annealing
temperature of 60°C. Signals were quantified using the
ΔΔCt method and normalized to β-actin levels.
Construction of lentiviral vectors
DNA oligonucleotides to produce plasmid-based small
hairpin RNA (shRNA) were cloned into the pLeno–
green fluorescent protein (GFP) vector. The shRNA tar-
get sequences for UCA1 were GGACAACAGTACACG
CATA (sh-1) and TTAATCCAGGAGACAAAGA (sh-2);
a scrambled sequence, which does not share obvious
homology with human gene sequences, was used as a
negative control. The pLeno-GFP vector and packing
vectors (pRsv-REV, pMDIg-pRRE, and PMD2G) were
cotransfected into 293T cells using Lipofectamine 2000
according to the manufacturer’s instructions. After 48 h,
the supernatant was collected, concentrated by centri-
fugation, and filtered through 0.45-μm cellulose acetate
filters. The titer was measured by counting the GFP-
positive cells under a fluorescence microscope (Olym-
pus, Tokyo, Japan). FaDu cells in 6-well plates were
infected with the constructed lentiviruses at a multipli-
city of infection of 60. The infection efficiency was
determined by counting the GFP-positive cells under a
fluorescence microscope 96 h after infection. The effi-
ciency of UCA1 silencing was subsequently quantified
by qRT-PCR (Fig. 1).
Apoptosis analysis
The Annexin V–allophycocyanin apoptosis detection kit
(eBioscience, San Diego, CA, USA) was used to identify
apoptotic cells. Briefly, FaDu cells were seeded in 6-well
plates following 5 days of lentiviral infection at a multi-
plicity of infection of 60. After being trypsinized and
washed twice with phosphate-buffered saline (PBS), the
FaDu cells were stained with Annexin V–fluorescein iso-
thiocyanate and propidium iodide (PI) successively in
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the staining buffer at 4°C in the dark and then detected
by flow cytometry with the FACSCalibur system (BD
Biosciences, San Diego, CA, USA).
Cell cycle analysis
FaDu cells were seeded in 60-mm dishes and infected
with the lentivirus for 24 h. Cells were harvested and
washed twice with cold PBS and then fixed with ice-cold
70% ethanol for 1 h at 4°C. After centrifugation at 1500
r/min for 5 min, the cells were washed twice with
PBS and resuspended with 0.5 ml of PBS containing
PI (50 μg/ml) and Rnase (100 μg/ml). The cells were
then stained at room temperature in the dark for 15
min, and the cell cycle distribution was assessed by
flow cytometry and analyzed using ModiFit 3.0 soft-
ware (Becton Dickinson).
Colony formation assay
We used a colony formation assay to assess the effect of
UCA1 knockdown on FaDu cell colony formation.
Briefly, stably transfected FaDu cells were sufficiently
trypsinized and suspended in DMEM supplemented with
10% FBS. The cells were then seeded in 6-well plates
in triplicate (800 cells/well) and maintained in a hu-
midified atmosphere containing 5% CO2 at 37°C. The
medium was changed every 3 days. After culture for
14 days, cell colonies were washed with PBS, fixed
with 4% paraformaldehyde for 30–60 min, and then
stained with Giemsa (ECM550 Chemicon, CA, USA)
for 20 min. Only colonies containing more than 50
cells were counted.
Transwell assays
To assess the invasiveness of FaDu cells, we used trans-
well chambers (Corning, Tewksbury, MA, USA) coated
with Matrigel (BD Biosciences). Fully trypsinized,
transfected cells (1 × 105 cells in 100 μl of serum-free
DMEM) were plated into the upper chamber. DMEM
(500 μl) supplemented with 20% FBS was added to the
lower chamber. After incubation in a humidified atmos-
phere containing 5% CO2 at 37°C for 72 h, FaDu cells
that had invaded the lower chamber were fixed with
methanol and stained with Giemsa. We used an
inverted microscope (magnification 200×) to count the
invading cells manually.
Statistical analysis
All experiments were repeated at least 3 times. Data
were presented as the mean ± the standard deviation and
analyzed with the SPSS software program (version 20.0).
P values < 0.05 were considered statistically significant.
The relationship between clinicopathological characteris-
tics and UCA1 expression was analyzed using the chi
square test or Fisher exact test. The Student t test was
used to assess differences between two experiment groups.
We used the Kaplan-Meier method to create survival
curves for patients with high or low UCA1 expression and
used a log-rank test to compare overall survival rates.
Results
UCA1 is overexpressed in HSCC tumor tissues
To confirm that UCA1 is upregulated in HSCC tumor
tissues, we performed qRT-PCR to measure the relative
expression levels of UCA1 in 53 pairs of HSCC tumor
tissues and their corresponding adjacent non-tumor mu-
cosae. The relative expression level of UCA1 in the
HSCC tissues (0.0088 ± 0.0050) was significantly higher
than that in the paired adjacent normal tissues (0.0051 ±
0.0040, P < 0.05; Fig. 1), which suggests that UCA1 is in-
volved in the pathogenesis of HSCC.
Association between UCA1 expression and
clinicopathological characteristics and survival
To further investigate the relationship between the UCA1
expression level and clinicopathological characteristics, we
divided the 53 patients into high– and the low–UCA1 ex-
pression groups according to the patients’ overall median
UCA1 expression level. As shown in Table 1, high UCA1
expression levels were significantly correlated with ad-
vanced T category (P = 0.034), late clinical stage (P =
0.021), and worse lymph node metastasis (P = 0.02). How-
ever, we found no significant correlation between UCA1
expression and other clinicopathological features such
as age and differentiation. Moreover, we found that the
overall survival rate of patients with high UCA1 expres-
sion was significantly lower than that of patients with
low UCA1 expression (P < 0.0001; Fig. 2). Together,
these data indicate that UCA1 might promote the
development of HSCC and be used as a prognostic
marker for the disease.
Fig. 1 UCA1 expression levels in HSCC tissues and paired adjacent
normal tissues. qRT-PCR was used to assess the relative expression of
UCA1 in two groups of samples, and β-actin was used as a normalization
control. n= 53; **P< 0.01
Qian et al. Molecular Cancer  (2017) 16:68 Page 3 of 7
Influence of UCA1 depletion on proliferation, apoptosis,
and cell cycle in FaDu cells
Loss-of-function experiments in vitro were conducted to
investigate the biological function of UCA1 in FaDu
cells. The UCA1 expression levels of FaDu cells trans-
fected with UAC1 siRNA (sh-1 or sh-2) were signifi-
cantly lower than that of FaDu cells transfected with the
scrambled sequence (Fig. 3a). The colony formation assay
demonstrated that UCA1-depleted FaDu cells formed sig-
nificantly fewer colonies than FaDu cells transfected with
the scramble sequence did (Fig. 3b), indicating that UCA1
has a role in promoting the proliferation of FaDu cells.
We also studied whether UCA1 promotes the prolifer-
ation of FaDu cells by influencing apoptosis or cell cycle
distribution. Flow cytometry revealed that lentiviral
transfection with either UCA1 siRNA (sh-1 or sh-2) in-
duced apoptosis in FaDu cells (Fig. 4a), indicating that
UCA1 has an anti-apoptotic role. The cell cycle analysis
revealed that, compared with transfection with the
scrambled siRNA, transfection with either UCA1 siRNA
(sh-1 or sh-2) caused a significantly larger accumulation
of FaDu cells in G0/G1 phase and a reduction of the
cells in S phase (Fig. 4b).
Given these findings, we hypothesized that the upregu-
lation of UCA1 contributes to the proliferation of HSCC
cells by exerting anti-apoptotic effects and promoting
cell cycle progression.
UCA1 contributes to metastasis by increasing the invasive
ability of FaDu cells
Considering that we found UCA1 expression to be sig-
nificantly correlated with the lymph node metastasis of
HSCC, we used transwell assays to further investigate
the role of UCA1 in promoting HSCC invasion. The
knockdown of UCA1 in FaDu cells significantly attenu-
ated their invasive ability (Fig. 5), suggesting that UCA1
has a role in enhancing the invasion of HSCC cells.
UCA1 was also identified as a pro-metastatic factor in
HSCC cells.
Discussion
HSCC, which is characterized by poor differentiation,
early lymph node metastasis, and negligible symptoms in
its early stages, is one of the worst head and neck squa-
mous cell carcinomas. Despite advances in HSCC treat-
ment strategies, HSCC patient outcomes remain quite
poor [20]. The lack of early-stage diagnostic markers
and novel therapeutic targets for HSCC emphasizes the
need to quickly obtain an improved understanding the
molecular mechanisms involved in HSCC development
and progression.
With the development of sequencing technology, an
increasing number of lncRNAs have been found to be
differentially expressed in cancers and normal tissues.
Among these differentially expressed lncRNAs, several
are emerging as important regulators of essential bio-
logical processes in cancer, such as apoptosis, cell prolif-
eration, cell cycle, and metastasis [21]. Among the
transcripts our microarray data have revealed to be dys-
regulated [19], the lncRNA UCA1, which has an onco-
genic role in several types of cancer, may help modulate
the pathogenesis of HSCC [22].
Through validation experiments for microarray re-
sults, upregulation of UCA1 in HSCC tumor tissues
was confirmed. Further, our analysis revealed that a
high UCA1 expression level is significantly associated
Table 1 Clinicopathological characteristics of HSCC patients and
relative expression of UCA1
Characteristics Cases UCA1 relative expression P value
Low High
Age, years 0.213
< 60 28 12 16
≥ 60 25 15 10
T category 0.034
T1-T2 22 15 7
T3-T4 31 12 19
Lymph node metastasis 0.020
N0 27 18 9
N1-2 26 9 17
Clinical stage 0.021
I-II 16 12 4
III-IV 37 15 22
Differentiation 0.613
Well 8 5 3
Moderate 21 9 12
Poor 24 13 11
Fig. 2 Kaplan–Meier analysis demonstrated that patients with high
UCA1 expression had a significantly worse prognosis than those
with low UCA1 expression did. ***P < 0.0001, log-rank test
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with advanced T category, late clinical stage, and worse
prognosis, and these findings are consistent with those
in other cancers, such as colorectal cancer and ovarian
cancer. Further, our in vitro experiments revealed that
UCA1 contributes to the proliferation of FaDu cells,
likely by inhibiting apoptosis and facilitating cell cycle
progression. These data partly explain the significance
of UCA1 upregulation in HSCC tumor tissues and its
relationship with related clinicopathological features.
However, additional investigation is needed to identify
the detailed molecular mechanisms underlying UCA1’s
oncogenic roles.
Fig. 3 UCA1 depletion inhibited the proliferation of FaDu cells. a qRT-PCR was used to quantify the silencing efficiency of UCA1. n = 3; **P < 0.01.
b Colony formation assays were used to assess the proliferation of FaDu cells transfected after culture for 14 days. Representative and quantitative
results are shown. n = 3; **P < 0.01
Fig. 4 Silencing of UCA1 induced apoptosis and cell cycle arrest in FaDu cells. a Flow cytometry was used to assess the percentage of apoptotic
FaDu cells after transfection for 5 days. Representative scatter plots and quantitative results are shown. n = 3; ** P < 0.01. b Flow cytometry was
used to assess the cell cycle distribution of FaDu cells transfected for 24h and stained with PI. Representative and quantitative results are shown.
n = 3; ** P < 0.01
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Recently, several groups have presented evidence that
UCA1 functions as a competing endogenous RNA in
cancer cells. For example, Nie et al. reported that UCA1
was a tumor promoter in non–small cell lung cancer
and that UCA1 upregulated the expression of the miR-
193a-3p target gene ERBB4 through competitively
“sponging” miR-193a-3p [23]. Wang et al. reported that
the depletion of UCA1 inhibited the growth and metas-
tasis of hepatocellular carcinoma cell lines in vitro and
in vivo, probably by directly binding to miR-216b and
downregulating miR-216b expression [24]. In addition,
Brian et al demonstrated that UCA1 promoted the pro-
liferation of colorectal cancer cells by physically binding
to and inhibiting miR-204-5p [25]. These findings sug-
gest that sponging certain miRNAs may be the under-
lying mechanism by which UCA1 is involved in the
proliferation, apoptosis regulation, and the cell cycle of
HSCC cells. In future studies, we will use TargetScan to
search for potential miRNA targets of UCA1 and use
RIP and qRT-PCR to identify them.
In accordance with others’ findings [22], we observed
that UCA1 also promoted the metastasis of HSCC cells.
Although UCA1 has been found to have a pro-metastatic
role in several types of cancers, its pathway and down-
stream targets remain largely unknown. However, recent
evidence has shown that UCA1 is involved with the Wnt6
and PI3 kinase/CREB pathways [26, 27], which are closely
related to epithelial-to-mesenchymal transition. Thus, we
thought that we could find the molecular mechanism of
UCA1 regarding its pro-metastatic effect, with the in-
creasingly enhanced understanding of its relevant path-
ways. One of major limitations of this study is that our
findings were observed for UCA1 in FaDu cells only,
while it would be advantageous if the effect of more
than one lncRNA is assessed in the both tumor sam-
ples and more than one cell line model. However, cur-
rently, in China, we only have one cell line of HSCC is
available for in vitro study. Additionally, information
on smoking and alcohol use should be included for ad-
justment for future prognosis analysis. Therefore, we
will confirm our results in other HSCC cell lines and
including smoking and alcohol information for adjust-
ment in our future studies once they become available.
Thus, the roles of UCA1 in HSCC warrant further
study once other cell lines of HSCC become available.
Conclusion
In conclusion, our study is the first to reveal the rela-
tionship between UCA1 expression and the clinical fea-
tures of HSCC patients and demonstrate that UCA1
might serve as a prognostic biomarker of HSCC. We
also identified an oncogenic role for UCA1 in the apop-
tosis, cell cycle, proliferation, and invasion in FaDu cells.
These findings lay the foundation for future studies
assessing the mechanisms of UCA1’s oncogenic actions.
Abbreviations
lncRNA: Long noncoding RNA; HSCC: Hypopharyngeal squamous cell
carcinoma; UCA1: Urothelial carcinoma-associated 1; qRT-PCR: Quantitative




This work was supported by the Taishan Scholars Program (No. tshw20130950),
Shandong Province; the Department of Science & Technology of Shandong
Province (No. ZR2013HM107, ZR2014HM005, 2015GSF118014, and
2015GSF118030); the Science Foundation of Qilu Hospital of Shandong
Fig. 5 Knockdown of UCA1 weakened the invasive ability of FaDu cells. A transwell assay was conducted to assess the invasion of FaDu
cells transfected with UCA1-siRNA (i.e. sh-1 and sh-2) and that of FaDu cells transfected with the scrambled control. Representative and
quantitative results are shown. n = 3; ** P < 0.01
Qian et al. Molecular Cancer  (2017) 16:68 Page 6 of 7
University; and the Fundamental Research Funds of Shandong University
(No.2014QLKY05).
Availability of data and materials
Data and materials will be shared.
Authors’ contributions
YQ, DL, XP, and DL carried out the majority of the experiment, data analysis,
and wrote the manuscript. They were all helped by SC, DW, WL, and GL. All
authors reviewed and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
All patients provided their written informed consent for their data and
tissues for the study.
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Qilu
Hospital of Shandong University.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Author details
1Department of Otorhinolaryngology, Qilu Hospital, Shandong University; Key
Laboratory of Otolaryngology, NHFPC (Shandong University), 107 West
Wenhua Road, Jinan, Shandong 250012, People’s Republic of China.
2Department of Otolaryngology & Head and Neck Surgery, 2nd Affiliated
Hospital of Anhui Medical University, Hefei, China. 3Department of Head and
Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston,
TX 77030, USA. 4Department of Epidemiology, The University of Texas MD
Anderson Cancer Center, Houston, TX 77030, USA.
Received: 17 February 2017 Accepted: 8 March 2017
References
1. Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KK, et al. National
Cancer Database report on cancer of the head and neck: 10-year update.
Head Neck. 2009;31:748–58.
2. Hall SF, Groome PA, Irish J, O’Sullivan B. The natural history of patients with
squamous cell carcinoma of the hypopharynx. Laryngoscope. 2008;118:
1362–71.
3. Takes RP, Strojan P, Silver CE, Bradley PJ, Haigentz Jr M, Wolf GT, et al.
Current trends in initial management of hypopharyngeal cancer: the
declining use of open surgery. Head Neck. 2012;34:270–81.
4. Jang JY, Kim EH, Cho J, Jung JH, Oh D, Ahn YC, et al. Comparison of
oncological and functional outcomes between initial surgical versus non-
surgical treatments for hypopharyngeal cancer. Ann Surg Oncol. 2016;23:
2054–61.
5. Guttman M, Rinn JL. Modular regulatory principles of large non-coding
RNAs. Nature. 2012;482:339–46.
6. Jia H, Osak M, Bogu GK, Stanton LW, Johnson R, Lipovich L. Genome-wide
computational identification and manual annotation of human long
noncoding RNA genes. RNA. 2010;16:1478–87.
7. Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises
from the RNA world. Genes Dev. 2009;23:1494–504.
8. Arriaga-Canon C, Fonseca-Guzman Y, Valdes-Quezada C, Arzate-Mejia R, Guerrero
G, Recillas-Targa F. A long non-coding RNA promotes full activation of adult gene
expression in the chicken alpha-globin domain. Epigenetics. 2014;9:173–81.
9. Peter S, Borkowska E, Drayton RM, Rakhit CP, Noon A, Chen W, et al.
Identification of differentially expressed long noncoding RNAs in bladder
cancer. Clin Cancer Res. 2014;20:5311–21.
10. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology.
Cancer Discov. 2011;1:391–407.
11. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and
cancer: a new frontier of translational research? Oncogene. 2012;31:4577–87.
12. Gibb EA, Brown CJ, Lam WL. The functional role of long non-coding RNA in
human carcinomas. Mol Cancer. 2011;10:38.
13. Reis EM, Verjovski-Almeida S. Perspectives of long non-coding RNAs in
cancer diagnostics. Front Genet. 2012;3:32.
14. Wang F, Li X, Xie X, Zhao L, Chen W. UCA1, a non-protein-coding RNA up-
regulated in bladder carcinoma and embryo, influencing cell growth and
promoting invasion. FEBS Lett. 2008;582:1919–27.
15. Huang J, Zhou N, Watabe K, Lu Z, Wu F, Xu M, et al. Long non-coding RNA
UCA1 promotes breast tumor growth by suppression of p27 (Kip1). Cell Death
Dis. 2014;5:e1008.
16. Han Y, Yang YN, Yuan HH, Zhang TT, Sui H, Wei XL, et al. UCA1, a long non-
coding RNA up-regulated in colorectal cancer influences cell proliferation,
apoptosis and cell cycle distribution. Pathology. 2014;46:396–401.
17. Zheng Q, Wu F, Dai WY, Zheng DC, Ye H, Zhou B, et al. Aberrant expression
of UCA1 in gastric cancer and its clinical significance. Clin Transl Oncol.
2015;17:640–6.
18. Li JY, Ma X, Zhang CB. Overexpression of long non-coding RNA UCA1
predicts a poor prognosis in patients with esophageal squamous cell
carcinoma. Int J Clin Exp Pathol. 2014;7:7938–44.
19. Zhou J, Li W, Jin T, Xiang X, Li M, Wang J, et al. Gene microarray analysis
of lncRNA and mRNA expression profiles in patients with hypopharyngeal
squamous cell carcinoma. Int J Clin Exp Med. 2015;8:4862–82.
20. Zhou J, Li M, Yu W, Li W, Wang J, Xiang X, et al. AB209630, a long non-
coding RNA decreased expression in hypopharyngeal squamous cell
carcinoma, influences proliferation, invasion, metastasis, and survival.
Oncotarget. 2016;7:14628–38.
21. Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21:1253–61.
22. He A, Hu R, Chen Z, Liao X, Li J, Wang D, et al. Role of long noncoding RNA
UCA1 as a common molecular marker for lymph node metastasis and
prognosis in various cancers: a meta-analysis. Oncotarget. 2016;8:1937–43.
23. Nie W, Ge HJ, Yang XQ, Sun X, Huang H, Tao X, et al. LncRNA-UCA1 exerts
oncogenic functions in non-small cell lung cancer by targeting miR-193a-
3p. Cancer Lett. 2016;371:99–106.
24. Wang CC, Liu HE, Lee YL, Huang YW, Chen YJ, Liou JP, et al. MPT0B169, a
novel tubulin inhibitor, induces apoptosis in taxol-resistant acute myeloid
leukemia cells through mitochondrial dysfunction and Mcl-1
downregulation. Tumour Biol. 2016;37:6065–72.
25. Bian Z, Jin L, Zhang J, Yin Y, Quan C, Hu Y, et al. LncRNA-UCA1 enhances
cell proliferation and 5-fluorouracil resistance in colorectal cancer by
inhibiting miR-204-5p. Sci Rep. 2016;6:23892.
26. Fan Y, Shen B, Tan M, Mu X, Qin Y, Zhang F, et al. Long non-coding RNA
UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt
signaling. FEBS J. 2014;281:1750–8.
27. Wang Y, Chen W, Yang C, Wu W, Wu S, Qin X, et al. Long non-coding RNA
UCA1a (CUDR) promotes proliferation and tumorigenesis of bladder cancer.
Int J Oncol. 2012;41:276–84.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Qian et al. Molecular Cancer  (2017) 16:68 Page 7 of 7
